In the remaining five patients, standard therapy was unclear due to the lack of information on HER2 and/or hormone receptor status (in three patients with DCIS, standard systemic therapy was considered as hormone therapy although information on HER2 status was lacking). This evidence concerns the gene NR4A1 and ductal breast carcinoma in situ.